Intervention Review

You have full text access to this OnlineOpen article

Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease

  1. Nilesh Chande1,*,
  2. David J Tsoulis2,
  3. John K MacDonald2

Editorial Group: Cochrane Inflammatory Bowel Disease and Functional Bowel Disorders Group

Published Online: 30 APR 2013

Assessed as up-to-date: 13 JUN 2012

DOI: 10.1002/14651858.CD000545.pub4

How to Cite

Chande N, Tsoulis DJ, MacDonald JK. Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease. Cochrane Database of Systematic Reviews 2013, Issue 4. Art. No.: CD000545. DOI: 10.1002/14651858.CD000545.pub4.

Author Information

  1. 1

    London Health Sciences Centre - Victoria Hospital, London, Ontario, Canada

  2. 2

    Robarts Research Institute, Robarts Clinical Trials, London, Ontario, Canada

*Nilesh Chande, London Health Sciences Centre - Victoria Hospital, Room E1-423A, 800 Commissioners Road East, London, Ontario, N6A 5W9, Canada. nchande2@uwo.ca.

Publication History

  1. Publication Status: Edited (no change to conclusions)
  2. Published Online: 30 APR 2013

SEARCH

[Figure 1]
Figure 1. Study flow diagram.
[Figure 2]
Figure 2. Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
[Analysis 1.1]
Analysis 1.1. Comparison 1 Azathioprine or 6-Mercaptopruine versus placebo, Outcome 1 Clinical remission.
[Analysis 1.2]
Analysis 1.2. Comparison 1 Azathioprine or 6-Mercaptopruine versus placebo, Outcome 2 Clinical remission or improvement.
[Analysis 1.3]
Analysis 1.3. Comparison 1 Azathioprine or 6-Mercaptopruine versus placebo, Outcome 3 Clinical remission or improvement (sensitivity analysis).
[Analysis 1.4]
Analysis 1.4. Comparison 1 Azathioprine or 6-Mercaptopruine versus placebo, Outcome 4 Clinical remission or improvement by trial duration.
[Analysis 1.5]
Analysis 1.5. Comparison 1 Azathioprine or 6-Mercaptopruine versus placebo, Outcome 5 Fistula improvement or healing.
[Analysis 1.6]
Analysis 1.6. Comparison 1 Azathioprine or 6-Mercaptopruine versus placebo, Outcome 6 Steroid sparing effect (final prednisone dose < 10 mg/day).
[Analysis 1.7]
Analysis 1.7. Comparison 1 Azathioprine or 6-Mercaptopruine versus placebo, Outcome 7 Adverse events.
[Analysis 1.8]
Analysis 1.8. Comparison 1 Azathioprine or 6-Mercaptopruine versus placebo, Outcome 8 Withdrawals due to adverse events.
[Analysis 1.9]
Analysis 1.9. Comparison 1 Azathioprine or 6-Mercaptopruine versus placebo, Outcome 9 Serious adverse events.
[Analysis 2.1]
Analysis 2.1. Comparison 2 Azathioprine versus Infliximab, Outcome 1 Clinical remission through 26 weeks.
[Analysis 2.2]
Analysis 2.2. Comparison 2 Azathioprine versus Infliximab, Outcome 2 Steroid-free remission through 26 weeks.
[Analysis 2.3]
Analysis 2.3. Comparison 2 Azathioprine versus Infliximab, Outcome 3 Mucosal healing through 26 weeks.
[Analysis 2.4]
Analysis 2.4. Comparison 2 Azathioprine versus Infliximab, Outcome 4 Adverse events.
[Analysis 2.5]
Analysis 2.5. Comparison 2 Azathioprine versus Infliximab, Outcome 5 Withdrawals due to adverse events.
[Analysis 2.6]
Analysis 2.6. Comparison 2 Azathioprine versus Infliximab, Outcome 6 Serious adverse events through 54 weeks.
[Analysis 3.1]
Analysis 3.1. Comparison 3 Azathioprine and Infliximab versus Infliximab, Outcome 1 Clinical remission.
[Analysis 3.2]
Analysis 3.2. Comparison 3 Azathioprine and Infliximab versus Infliximab, Outcome 2 Steroid-free clinical remission.
[Analysis 3.3]
Analysis 3.3. Comparison 3 Azathioprine and Infliximab versus Infliximab, Outcome 3 Mucosal healing through 26 weeks.
[Analysis 3.4]
Analysis 3.4. Comparison 3 Azathioprine and Infliximab versus Infliximab, Outcome 4 Adverse events.
[Analysis 3.5]
Analysis 3.5. Comparison 3 Azathioprine and Infliximab versus Infliximab, Outcome 5 Withdrawals due to adverse events.
[Analysis 3.6]
Analysis 3.6. Comparison 3 Azathioprine and Infliximab versus Infliximab, Outcome 6 Serious adverse events.
[Analysis 4.1]
Analysis 4.1. Comparison 4 Azathioprine or 6-Mercaptopurine versus Methotrexate, Outcome 1 Steroid-free remission.
[Analysis 4.2]
Analysis 4.2. Comparison 4 Azathioprine or 6-Mercaptopurine versus Methotrexate, Outcome 2 Adverse events.
[Analysis 4.3]
Analysis 4.3. Comparison 4 Azathioprine or 6-Mercaptopurine versus Methotrexate, Outcome 3 Withdrawals due to adverse events.
[Analysis 5.1]
Analysis 5.1. Comparison 5 Azathioprine or 6-Mercaptopurine versus 5-Aminosalicylic acid or Sulfasalazine, Outcome 1 Steroid-free clinical remission.
[Analysis 5.2]
Analysis 5.2. Comparison 5 Azathioprine or 6-Mercaptopurine versus 5-Aminosalicylic acid or Sulfasalazine, Outcome 2 Withdrawals due to adverse events.
[Analysis 5.3]
Analysis 5.3. Comparison 5 Azathioprine or 6-Mercaptopurine versus 5-Aminosalicylic acid or Sulfasalazine, Outcome 3 Serious adverse events.